Highlights Allogene Therapeutics, Inc.

Equities

ALLO

US0197701065

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.89 ^USD	+1.23%		-16.71%	-9.97%

Apr. 26	Allogene Therapeutics Gets $15 Million Grant from California Institute for Regenerative Medicine for Cancer Drug Development	MT
Apr. 26	Allogene Therapeutics Receives Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Allogene Therapeutics Gets $15 Million Grant from California Institute for Regenerative Medicine for Cancer Drug Development	Apr. 26	MT
Allogene Therapeutics Q4 Loss Narrows, Revenue Drops	Mar. 14	MT
Allogene Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 14	CI
Allogene Therapeutics to Restate Financial Statements Due to Accounting Adjustments	Feb. 16	MT
North American Morning Briefing : Boeing Drags -2-	Jan. 08	DJ
Allogene Therapeutics to Lay off 22% of Workforce; Partners With Foresight to Develop in Vitro Diagnostic	Jan. 05	MT
Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-Based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma	Jan. 04	CI
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of Car T Led by ALPHA3	Jan. 04	CI
Allogene Therapeutics, Inc. Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647	Dec. 09	CI
Allogene Therapeutics, Inc. Presents Preclinical Data on Next Generation Cloak and Dagger Technologies At the Society for Immunotherapy of Cancer Annual Meeting	Nov. 03	CI
Allogene Therapeutics, Inc. Presents Preclinical Data on Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 At the Society for Immunotherapy of Cancer Annual Meeting	Nov. 03	CI
Allogene Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023	Nov. 02	CI
Allogene Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02	CI
Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma Lugano	23-06-15	CI
Allogene Therapeutics, Inc. Presents Long-Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials of ALLO-501/501A in Patients with Relapsed/Refractory Large B-Cell Lymphoma at American Society of Clinical Oncology Annual Meeting in Chicago, Illinois	23-06-03	CI
Allogene Therapeutics, Inc. Announces Encore Presentation of Phase 1 Data from the Allo-501/501A Trials in Large B Cell Lymphoma At the European Hematology Association Hybrid Congress	23-05-11	CI
ALLOGENE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	23-05-03	AQ
Allogene Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-03	CI
Allogene Therapeutics, Inc. Announces Oral Presentation of Phase 1 Data on ALLO-316 At the American Association of Cancer Research Annual Meeting	23-03-14	CI
Allogene Therapeutics, Inc. Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy	23-03-01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Allogene Therapeutics, Inc.

Equities

ALLO

US0197701065

Highlights

Filters